AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 312.9 USD | +1.81% |
|
+12.38% | +8.62% |
| May. 09 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
| May. 09 | Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170 | MT |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 0 M€ | +15.32% | - | |
| 3.71% | 0 M€ | +6.39% | - | |
| 3.24% | 0 M€ | -2.17% | - | |
| 2.61% | 1 M€ | +2.21% | - | |
| 1.75% | 4,592 M€ | +11.18% | ||
| 1.73% | 9 M€ | -4.31% | - | |
| 1.67% | 9 M€ | -.--% | - | |
| 1.65% | 0 M€ | -.--% | ||
| 1.55% | 0 M€ | +5.36% | ||
| 1.37% | 2 M€ | +20.44% | - | |
| 1.31% | 5 M€ | -72.95% | - | |
| 1.29% | 0 M€ | 0.00% | - | |
| 1.19% | 0 M€ | 0.00% | - | |
| 1.04% | 3,859 M€ | +18.82% | - | |
| 1.04% | 469 M€ | -2.05% | - | |
| 1.04% | 0 M€ | +2.15% | ||
| 0.88% | 0 M€ | +8.89% | ||
| 0.77% | 0 M€ | +5.55% | - | |
| 0.75% | 7 M€ | +0.11% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
307.3
USD
Average target price
313.3
USD
Spread / Average Target
+1.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.62% | 165B | |
| +32.36% | 698B | |
| +26.51% | 568B | |
| -4.40% | 358B | |
| +19.46% | 328B | |
| +3.50% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +3.81% | 125B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.